Drug Sponsors

Shire acquires Fibrotech for $75M

Friday, May 2, 2014 11:32 AM

Shire, a global specialty biopharmaceutical company, has acquired Fibrotech, an Australian biopharmaceutical company developing a new class of drugs associated with fibrosis, for an up-front payment of $75 million plus certain development and regulatory milestone payments.

More... »

WIRB Copernicus Group

Endo to acquire Somar

Thursday, May 1, 2014 10:29 AM

Endo International will acquire Grupo Farmaceutico Somar, a privately owned specialty pharmaceuticals company based in Mexico City, Mexico. Endo expects the transaction to be immediately accretive to adjusted earnings per share. Financial details have not been disclosed.

More... »

CRF Health eCOA webinar series

Bristol-Myers Squibb acquires iPierian

Wednesday, April 30, 2014 11:39 AM

Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain.

More... »

Forest Labs’ $1.46 billion acquisition of Furiex strengthens GI business

Tuesday, April 29, 2014 03:24 PM

By Ronald Rosenberg
CenterWatch Staff Writer

The pharmaceutical industry’s shopping spree for specific disease expertise or scale continued this week as Forest Laboratories announced plans to acquire Furiex Pharmaceuticals for up to $1.46 billion, including milestone payments.

More... »

Pfizer pursues AstraZeneca for potential $100 billion acquisition deal

Monday, April 28, 2014 02:15 PM

By Ronald Rosenberg
CenterWatch Staff Writer

Having rejected two bids since January, Pfizer made its next move on Monday—a $99 billion stock and cash offer to acquire AstraZeneca, to create a single U.K.-based company that would become the world’s largest pharmaceutical company.

More... »

Prestige Brands to acquire Insight Pharmaceuticals

Monday, April 28, 2014 01:11 PM

Prestige Brands Holdings has entered into a definitive agreement to acquire Insight Pharmaceuticals, a marketer and distributor of feminine care and other over-the-counter (OTC) healthcare products, for $750 million in cash. Prestige will acquire tax attributes with a present value of approximately $100 million, which results in an effective purchase price of approximately $650 million.

More... »

Zimmer Holdings to combine with Biomet for $13.35B

Friday, April 25, 2014 10:54 AM

Zimmer Holdings will acquire Biomet in a cash and stock transaction valued at approximately $13.35 billion, including the assumption of net debt. The transaction, which is subject to customary closing conditions and regulatory approvals, is expected to close in the first quarter of 2015.

More... »

Quintiles, Biogen Idec ink 5-year partnership

Thursday, April 24, 2014 01:04 PM

CRO Quintiles and Biogen Idec have entered into a five-year strategic clinical development agreement. The collaboration is designed to leverage the expertise and experience from both organizations to optimize Biogen Idec’s clinical development processes.

More... »

Allergan adopts one-year stockholder rights plan

Wednesday, April 23, 2014 02:16 PM

Irvine, Calif.-based Allergan has announced its board of directors has unanimously adopted a one-year stockholder rights plan effective April 22, and declared a dividend distribution of one preferred share purchase right on each outstanding share of the company's common stock.

More... »

Bio-Techne to acquire Shanghai PrimeGene Bio-Tech

Wednesday, April 16, 2014 01:40 PM

Techne, a developer, manufacturer and seller of biotechnology products and clinical controls, has announced that its R&D systems China subsidiary, a specialty manufacturer of biological products, has entered into an agreement to acquire 100% of Shanghai PrimeGene Bio-Tech.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs